Doug Treco, Ph.D.
EIR & CEO of Ra Pharmaceuticals
Doug joined Morgenthaler Ventures in early 2008 as an Entrepreneur-in-Residence in the Life Science Team. Shortly after joining the team, he took on the responsibilities of CEO of Ra Pharmaceuticals, Inc., a drug discovery start-up being incubated in Morgenthaler’s Boston office.
Doug received a Ph.D. degree in Biochemistry and Molecular Biology from SUNY Stony Brook and performed post-doctoral studies at the Salk Institute and Massachusetts General Hospital. In 1988 he co-founded Transkaryotic Therapies, Inc. (acquired in 2005 by Shire plc), a multi-platform biopharmaceutical company developing protein and gene therapy products. He has authored numerous peer-reviewed publications and holds 35 US and European patents in the areas of protein production, gene mapping and gene therapy.